In Wroclaw they are testing a new drug for atopic dermatitis in dogs

“Currently, there are drugs available on the market for the treatment of AD that work mainly symptomatically. Such therapy, unfortunately, does not produce long-term effects, and chronic use of such drugs increases the risk of side effects and resistance to the therapy. The drug we are currently working on – based on the immunomodulatory properties of mesenchymal stem cells – may be the answer here as a solution demonstrating both symptomatic and causal effects.”
-says Lukasz Bzdzion, CEO of Board of Directors of Bioceltix

A new safer and more effective therapy is already awaited by 15% of the dog population, and only in Poland, the percentage of dogs suffering from AD is even higher – according to a study last conducted in selected clinics in Poland last year, dogs with AD accounted for more than 28% of the cases.

Is this a problem with your dog?

If your dog scratches excessively and rubs against various objects, and on top of that, changes such as abrasions have recently appeared on his skin, darker color, pimples, papules or alopecia – these could be symptoms of AD.

“Changes on the skin are most often found on the muzzle, paws and sides of the body of our quadruped. The skin is inflamed and very itchy. The lesions can fade and return. At the same time, AD is a seasonal disease, i.e. its symptoms intensify during a specific period. Now we have just such a period, so it’s worth watching your dog more carefully.”
-advises veterinarian Marta Pasikowska, coordinator of the study conducted at the University of Wrocław University of Life Sciences from the Bioceltix website

Register your dog to participate in the pilot clinical trial in Wroclaw

Bioceltix and the Faculty of Veterinary Medicine at Wrocław University of Environmental and Life Sciences are inviting canine patients whose caregivers either notice symptoms of AD or have already received such a diagnosis from a veterinarian. The study is conducted under the approval of the Local Ethical Committee Ethical Committee in Wroclaw, in accordance with all applicable procedures and safety requirements.

“For our drug candidate for AD in dogs, we have completed the so-called Target Animal Safety, or safety phase, in which its intravenous administration was confirmed to be safe. As a result, we were able to proceed to the next stage, the pilot clinical trial, to which we are now inviting patients to.”
-says veterinarian Marta Pasikowska

For more information about the study and the canine patient application form:

https://bioceltix.com/zglos-swojego-psa-do-badania-klinicznego-nad-azs/

Bioceltix is a biotechnology company developing modern medicinal products for companion animals with a particular focus on dogs and horses. The company is developing proprietary technology for manufacturing biological drugs based on mesenchymal stem cells. The breakthrough of the Bioceltix approach is the use of a method enabling the administration of stem cells from a small number of healthy donors to a large number of patients, i.e. in an allogeneic model. The therapeutic products developed in this way will be available off-the-shelf, on-site at the veterinary clinic and ready to be administered to the patient immediately after thawing. The biological drugs being developed at Bioceltix biologics have the potential – in addition to having a symptomatic effect – to exhibit a causal effect by influencing the inflammatory environment and activating natural mechanisms of restoration of affected tissues.